287 related articles for article (PubMed ID: 33246373)
21. Satralizumab: First Approval.
Heo YA
Drugs; 2020 Sep; 80(14):1477-1482. PubMed ID: 32797372
[TBL] [Abstract][Full Text] [Related]
22. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
Kleiter I; Traboulsee A; Palace J; Yamamura T; Fujihara K; Saiz A; Javed A; Mayes D; Büdingen HV; Klingelschmitt G; Stokmaier D; Bennett JL
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36724181
[TBL] [Abstract][Full Text] [Related]
23. Urosepsis Risk in Neuromyelitis Optica Spectrum Disorder Patients Administered Satralizumab.
Fujita R; Aratake Y; Nakata K; Fujii C; Kondo T
Intern Med; 2023 Nov; 62(22):3317-3320. PubMed ID: 37032080
[TBL] [Abstract][Full Text] [Related]
24. Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options.
Rosso M; Saxena S; Chitnis T
Expert Rev Neurother; 2020 May; 20(5):509-516. PubMed ID: 32306778
[No Abstract] [Full Text] [Related]
25. Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient.
Pestchanker C; Diaconchuk M; Lopez P; Montaño MR; Romero W; Zalazar G; Carnero Contentti E
Mult Scler; 2023 Jan; 29(1):150-153. PubMed ID: 36437566
[TBL] [Abstract][Full Text] [Related]
26. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
Valencia-Sanchez C; Wingerchuk DM
BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
[TBL] [Abstract][Full Text] [Related]
28. Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder.
Magro G
Mult Scler Relat Disord; 2022 Sep; 65():104037. PubMed ID: 35835028
[TBL] [Abstract][Full Text] [Related]
29. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
Duchow A; Paul F; Bellmann-Strobl J
Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
[TBL] [Abstract][Full Text] [Related]
30. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.
Holmøy T; Høglund RA; Illes Z; Myhr KM; Torkildsen Ø
J Neurol; 2021 Dec; 268(12):4522-4536. PubMed ID: 33011853
[TBL] [Abstract][Full Text] [Related]
31. Neuromyelitis optica spectrum disorder safely and successfully treated with satralizumab during pregnancy and breastfeeding: a case report.
Yoshida T; Watanabe O; Nomura M; Yoshimoto Y; Maki Y; Takashima H
Front Neurol; 2023; 14():1322412. PubMed ID: 38162440
[TBL] [Abstract][Full Text] [Related]
32. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
Wallach AI; Tremblay M; Kister I
Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
[TBL] [Abstract][Full Text] [Related]
33. New therapies for neuromyelitis optica spectrum disorder.
Levy M; Fujihara K; Palace J
Lancet Neurol; 2021 Jan; 20(1):60-67. PubMed ID: 33186537
[TBL] [Abstract][Full Text] [Related]
34. Olamkicept(sgp130Fc): The missing trial in Neuromyelitis Optica Spectrum Disorder.
Magro G
Clin Immunol; 2022 Aug; 241():109072. PubMed ID: 35798242
[TBL] [Abstract][Full Text] [Related]
35. [Treatment and new evidences in neuromyelitis optica spectrum disorder].
Illés Z
Ideggyogy Sz; 2021 Sep; 74(9-10):309-321. PubMed ID: 34657404
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis.
Kharel S; Shrestha S; Ojha R; Guragain N; Ghimire R
BMC Neurol; 2021 Nov; 21(1):458. PubMed ID: 34814882
[TBL] [Abstract][Full Text] [Related]
37. [Neuromyelitis Optica Spectrum Disorder].
Misu T
Brain Nerve; 2021 May; 73(5):475-482. PubMed ID: 34006678
[TBL] [Abstract][Full Text] [Related]
38. Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience.
Sellner J; Sitte HH; Rommer PS
Drug Discov Today; 2021 Jul; 26(7):1591-1601. PubMed ID: 33781948
[TBL] [Abstract][Full Text] [Related]
39. Emerging drugs for the treatment of neuromyelitis optica.
Duchow A; Chien C; Paul F; Bellmann-Strobl J
Expert Opin Emerg Drugs; 2020 Sep; 25(3):285-297. PubMed ID: 32731771
[TBL] [Abstract][Full Text] [Related]
40. Utilization of FDA approved treatments for neuromyelitis optica spectrum disorder in clinical practice: A survey study of academic neuroimmunologists.
Thon JM; Sharkus R; Thakkar R; Hunter K; Siegler JE; Thon OR
Mult Scler Relat Disord; 2023 Dec; 80():105076. PubMed ID: 37866024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
